Navigation path

Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

5-amino-1-(2-methyl-1H-benzo[d]imidazol-5-yl)-1H-pyrazol-4-yl 1H-indol-2-yl ketone mono[(S)-2-hydroxysuccinate]

EU orphan designation number: EU/3/17/1916   
Active ingredient: 5-amino-1-(2-methyl-1H-benzo[d]imidazol-5-yl)-1H-pyrazol-4-yl 1H-indol-2-yl ketone mono[(S)-2-hydroxysuccinate]
Indication: Treatment of biliary tract cancer
Sponsor: Voisin Consulting S.A.R.L.
64 avenue Pierre Grenier, 92100 Boulogne Billancourt, France

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
18/10/2017 Orphan designation EMA/OD/124/17 (2017)7049 of 16/10/2017